Novartis completes agreement with Bayer Schering related to Betaseron rights and manufacturing

18-Sep-2007 - Novartis has completed an agreement with Bayer Schering Pharma AG (Bayer Schering) related to various rights for the multiple sclerosis treatment Betaseron® (interferon beta-1b) and has received a one-time payment of approximately USD 200 million. As part of the transaction, which was announced ...

Bayer completes acquisition of U.S. biologics manufacturing facility from Novartis

17-Sep-2007 - Bayer Schering Pharma AG, Germany, has completed the acquisition of a biologics manufacturing facility in Emeryville, California from Novartis. Bayer will manufacture its multiple sclerosis drug Betaseron® at the Emeryville site, retain full control of all manufacturing and process technology ...

Bayer HealthCare announces concrete plans for the global synergy goals and job cuts

06-Mar-2007 - Bayer HealthCare published concrete plans regarding the previously announced synergy goals. The integration of the activities of the former Schering AG, Germany, with the Pharma division of Bayer HealthCare shall result in annual savings of EUR 700 million from 2009. Adjustments to personnel ...

Bayer Outlines New Global R&D Structures

U.S. Pharma Sites and Future Headquarters

13-Nov-2006 - Bayer HealthCare announced a structural realignment of its global pharmaceutical research and development organization. The company also outlined its future U.S. pharma site plan, and said that New Jersey will be home to its U.S. headquarters for pharmaceuticals. These moves follow Bayer's ...

Go-ahead for Schering's integration into the Bayer Group

EUR 89.36 cash compensation offer to Schering's outside stockholders

09-Nov-2006 - The way is now clear for Schering AG to be integrated into the Bayer Group. The management of Bayer Schering GmbH (formerly Dritte BV GmbH) has resolved to execute the domination and profit and loss transfer agreement with Schering AG. "This is a milestone along the road to integrating Schering ...

Agreement between Bayer and Schering in force

Resolution of Schering Extraordinary Stockholders' Meeting implemented

02-Nov-2006 - Following the consent of the Extraordinary Stockholders' Meeting of Schering AG on September 13, 2006 to the domination and profit and loss transfer agreement with Bayer subsidiary Dritte BV GmbH, the agreement became effective on October 27, 2006 through its entry in the commercial register. An ...

Betaseron approved in the U.S. for earliest stages of Multiple Sclerosis

25-Oct-2006 - Schering AG announced that the U.S. Food and Drug Administration (FDA) has expanded the indication of Betaseron (interferon beta-1b, brand name of Betaferon® in the U.S.) to include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis. ...

Bayer controls 92.4 percent of outstanding Schering shares

14-Jul-2006 - Bayer's public takeover offer for Schering AG has been completed. Following expiration of the additional acceptance period, Bayer now has control of 92.4 percent of the approximately 191 million outstanding Schering shares. "This result is a great success," commented Bayer Management Board ...

Bayer and Schering optimistic about their common future

23-Jun-2006 - Following the success of Bayer's takeover offer for Schering, the two companies are confident about their common future. "We will combine two successful pharmaceutical companies to form a single, even more powerful unit and create a leading global enterprise," said Bayer Management Board Chairman ...

Bayer: Takeover offer for Schering successful

Bayer now controls 88.0 percent of issued and outstanding Schering shares

22-Jun-2006 - The way is now clear for the Bayer Group to acquire Berlin-based pharmaceuticals company Schering AG. Bayer has gained control of a total of 88.0 percent of Schering's approximately 191 million issued and outstanding shares. The attainment of a three-quarters majority was the last remaining ...